MolGraph
CompoundsDocumentationComplianceAbout
MolGraph

Research chemical sourcing and molecular building block RFQ workflows.

MolGraph is operated by Tessorix Inc.

support@molgraph.com

Products are intended for laboratory research use only and are not for human or veterinary use.

Compounds

  • Compound catalog
  • CAS Search

Company

  • About
  • Contact

Documentation

  • Quality Documentation
  • SDS Disclaimer

Compliance

  • Compliance

Legal

  • Terms
  • Privacy

Copyright © 2026 MolGraph. All Rights Reserved.

Home/Compounds/CAS 70458-92-3
Formula C17H20FN3O3MW 333.36Research-use catalog entryCOA/SDS by request

Pefloxacin

CAS Number: 70458-92-3

Sourcing & RFQ

Submit an RFQ to review pricing, availability, lead time, pack size, purity, COA, and supplier SDS for this catalog entry.

Available options

Available Options

Package
1 g
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
100 mg
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required
Package
250 mg
Purity
99%
Price
Request review
Availability
Shipping review required
Delivery
Shipping review required

Shipping review is required before pricing or stock can be confirmed publicly. Shipping, duties, and documentation fees are confirmed before order acceptance.

Loading RDKit molecule structure...
InChIKey: FHFYDNQZQSQIAI-UHFFFAOYSA-NC17H20FN3O3 | MW 333.36

Chemical Absolute Identifiers

CAS Number

70458-92-3

PubChem CID

51081

Molecular Formula

C17H20FN3O3

Molecular Weight

333.36 g/mol

Exact Mass

333.14887

InChIKey

FHFYDNQZQSQIAI-UHFFFAOYSA-N

IUPAC Name

1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid

SMILES String

CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCN(CC3)C)F)C(=O)O

Physical Properties

Melting Point

271.0 °C

Properties are provided as catalog reference data and may be confirmed through supplier documentation when required.

Catalog Facts

Structural features

Pefloxacin (CAS 70458-92-3) is listed in the Pharmaceutical Intermediates portfolio, with molecular formula C17H20FN3O3 and molecular weight 333. 36 g/mol.

Sourcing context

Catalog reference for RFQ preparation, supplier confirmation, and research chemical sourcing review.

Research use context

Intended for research-stage medicinal chemistry and intermediate synthesis workflows; structure-derived tags include nitrogen-containing heterocycle.

Documentation needs

COA/SDS status, availability, lead time, pack size, and shipment documentation can be confirmed during quotation.

Applications & Classification

Pharmaceutical Intermediate ResearchResearch intermediateCustom synthesis building blockPharmaceutical intermediate researchResearch chemical sourcingCustom synthesis and catalog availability reviewCOA, SDS, pricing, and fulfillment workflow
Biological target reference

ChEMBL reports experimental activity evidence for: DNA gyrase (Escherichia coli) — 6 assays; DNA topoisomerase 2-beta (Homo sapiens) — 6 assays; Histamine H1 receptor (Homo sapiens) — 3 assays; Nuclear receptor subfamily 1 group I member 2 (Homo sapiens) — 3 assays; 5-hydroxytryptamine receptor 1A (Homo sapiens) — 2 assays. These records describe research assays and do not establish therapeutic efficacy or clinical use.

DNA gyrase

Escherichia coli · PROTEIN COMPLEX · 6 qualifying assays · 3 documents

Experimental evidence source: ChEMBL

DNA topoisomerase 2-beta

Homo sapiens · SINGLE PROTEIN · 6 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Histamine H1 receptor

Homo sapiens · SINGLE PROTEIN · 3 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Nuclear receptor subfamily 1 group I member 2

Homo sapiens · SINGLE PROTEIN · 3 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

5-hydroxytryptamine receptor 1A

Homo sapiens · SINGLE PROTEIN · 2 qualifying assays · 1 documents

Experimental evidence source: ChEMBL

Safety & Handling

First Aid

  • Do not give anything to an unconscious person.
  • Rinse mouth with water.

Stability / Reactivity

  • Reactivity.
  • Carbon monoxide, carbon dioxide, hydrogen fluoride, nitrogen oxides.

Disposal

  • Dispose of remaining and non-recyclable solutions to a licensed company.
  • Contact a professional institution with a waste disposal license to handle this substance.
Show additional safety reference fields

Fire Fighting

  • If necessary, wear a self-contained breathing apparatus when fighting fires.

Accidental Release

  • Do not generate dust when collecting and disposing.
  • Sweep and shovel up.

For supplier-issued SDS, request documentation before handling, storage, shipment, or procurement decisions.

Preliminary Safety Reference

For supplier-issued SDS or COA, submit a documentation request.

Safety Reference / SDS Request

Names & Synonyms / External Identifiers

Chemical Name

Pefloxacin

Names & Synonyms

PefloxacinePefloxacino1-ethyl-6-fluoro-7-(4-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acidPefloxacinumPFLX
Show all synonyms
1589 RB3-Quinolinecarboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-pefloxacinaPefocinPefbidPefranPeloxPefloxacin, SilverMesylate, PefloxacinDihydrate, Pefloxacin MesylateMesylate Dihydrate, PefloxacinR.B., 2589PefloxaciniumPefloxacinium mesylate
External Identifiers
EC NUMBER: 274-611-8DSSTOX SUBSTANCE ID: DTXSID3048493CHEMBL ID: CHEMBL267648CHEBI ID: CHEBI:50199UNII: 2H52Z9F2Q5DRUGBANK ID: DB00487HMDB ID: HMDB0014630KEGG ID: D02306METABOLOMICS WORKBENCH ID: 42832NCI THESAURUS CODE: C728PHARMGKB ID: PA164742856
Experimental Spectrum References
13C NMR Spectra15N NMR Spectra
Literature & Patent References
DOI 10.1016/j.ejmech.2025.117245Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer.PMID 39793440Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer.DOI 10.1016/j.isci.2024.108907Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelPMID 38318365Identification and evaluation of small-molecule inhibitors against the dNTPase SAMHD1 via a comprehensive screening funnelDOI 10.1038/s41467-023-40064-9A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.PMID 37468498A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs.DOI 10.6019/CHEMBL4651402Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activityDOI 10.1101/2020.04.03.023846In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

Documentation & Compliance Facts

Compliance Facts

Shipment review: Required

Documentation available by request

Certificate of Analysis (COA): By request

Supplier Safety Data Sheet (SDS): By request

Purity and pack size confirmation: By request

Availability and lead time review: Confirmed by RFQ

Shipment documentation review: By request

For supplier-issued documentation by request, use the RFQ actions on this page.Review preliminary safety reference

What happens after RFQ

  1. 1We review the CAS identity, quantity, and documentation request.
  2. 2We check sourcing options, supplier availability, COA/SDS, purity, pack size, and lead time.
  3. 3We review destination and shipment documentation needs when applicable.
  4. 4We follow up with a quotation or clarification request.

Text Reference Cues

Show non-linked catalog cues

Non-public related references

NorfloxacinCAS 70458-96-7
FleroxacinCAS 79660-72-3
1,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrate (2:3)CAS 84294-96-2
Sarafloxacin HydrochlorideCAS 91296-87-6
Piromidic AcidCAS 19562-30-2

Non-public references are shown as text only and do not imply equivalence, availability, or shared use.

Catalog navigation

Related Catalog Entries

Other public CAS pages in this catalog. These links support navigation across additional intermediates and do not imply equivalence, availability, or shared use.

CAS 70458-96-7NorfloxacinCAS 79660-72-3FleroxacinCAS 84294-96-21,8-Naphthyridine-3-carboxylic acid, 1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-, hydrate (2:3)CAS 91296-87-6Sarafloxacin HydrochlorideCAS 19562-30-2Piromidic AcidCAS 107724-20-9EplerenoneCAS 114-07-8ErythromycinCAS 181695-72-7ValdecoxibCAS 389-08-2Nalidixic AcidCAS 1002310-00-0Tert-butyl 1-(2-chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethylcarbamate

RFQ questions for CAS 70458-92-3

What are the key identifiers for Pefloxacin (CAS 70458-92-3)?

Pefloxacin is identified by CAS 70458-92-3, with molecular formula C17H20FN3O3, molecular weight 333.36, InChIKey FHFYDNQZQSQIAI-UHFFFAOYSA-N.

Does CAS 70458-92-3 have reported biological target evidence?

ChEMBL contains qualifying experimental assay evidence associated with DNA gyrase, DNA topoisomerase 2-beta, Histamine H1 receptor, Nuclear receptor subfamily 1 group I member 2, 5-hydroxytryptamine receptor 1A. These records do not establish therapeutic efficacy or clinical use.

Can I request a COA for CAS 70458-92-3?

Yes. Submit an RFQ and specify COA requirements. Lot-specific COA depends on supplier confirmation.

Can I request supplier SDS for Pefloxacin?

Yes. Supplier SDS can be requested through the RFQ workflow before handling, storage, shipment, or procurement decisions.

Is CAS 70458-92-3 available for quotation?

Availability, pack size, lead time, and pricing are confirmed through RFQ.

Can MolGraph support bulk sourcing or custom synthesis review?

Submit the CAS number, quantity, purity requirement, and destination country for sourcing review.